Company news
Vivos Therapeutics, Inc. news in 2024
Vivos Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 22, 2024
Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update
November 13, 2024
Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call
November 12, 2024
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association
October 7, 2024
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
September 18, 2024
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
September 17, 2024
Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call
August 13, 2024
Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model
June 26, 2024
Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance
June 11, 2024
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call
May 13, 2024
Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update
May 13, 2024
Vivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical Devices
April 8, 2024
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call
March 27, 2024
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
March 27, 2024
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds
February 14, 2024
Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSA
January 7, 2024
Calls in 2024
- Vivos Therapeutics (NASDAQ:VVOS) Q3 2024 Earnings Call
Nov 14, 2024
Transcript - Vivos Therapeutics (NASDAQ:VVOS) Q2 2024 Earnings Call
Aug 14, 2024
Transcript - Vivos Therapeutics (NASDAQ:VVOS) Q1 2024 Earnings Call
May 14, 2024
Transcript - Vivos Therapeutics (NASDAQ:VVOS) Q4 2023 Earnings Call
Mar 28, 2024
Transcript